Join the Upper Limb Spasticity group to help and get support from people like you.
Upper Limb Spasticity News
MS May Begin Years Earlier Than Thought
MONDAY, Aug. 4, 2025 — People with multiple sclerosis (MS) begin experiencing new health issues up to 15 years before the classic signs of the illness appear, Canadian research shows. “MS can be dif...
Women Less Likely to Get Certain MS Meds Than Men
THURSDAY, July 31, 2025 — Women are less likely than men to receive multiple sclerosis (MS) meds that could help them manage the disease and delay disability, a new report finds. It could be that s...
Women With MS Less Likely Than Men to Receive Disease-Modifying Therapies
THURSDAY, July 31, 2025 – Women with multiple sclerosis (MS) are less likely to receive disease-modifying therapies (DMTs) than men, according to a study published online July 30 in Neurology....
Greater Epigenetic Age Seen in Patients With Pediatric-Onset MS
TUESDAY, June 17, 2025 – Individuals with pediatric-onset multiple sclerosis (POMS) have greater epigenetic age and age acceleration residual (AAR) compared with age-similar controls, according to a...
Experimental Drug Can Slow MS Disability
WEDNESDAY, April 9, 2025 – An experimental drug can help patients with advanced multiple sclerosis (MS) delay the progressive disability that comes with their disorder, a new clinical trial...
AAN: Tolebrutinib Slows Disability in Nonrelapsing Secondary Progressive MS
WEDNESDAY, April 9, 2025 – Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation within the central nervous system, slows...
MS Patients May Benefit From Eating More Fish
WEDNESDAY, Feb. 26, 2025 – A diet rich in fish might slow the progression of multiple sclerosis in some patients, a new study says. The nutrients found in fish can quell inflammation and protect...
Anti-CD20 Therapy Shows No Effect on Disability Progression in MS
THURSDAY, Sept. 26, 2024 – For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and...
FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS
THURSDAY, Sept. 26, 2024 – The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection...
FDA Approves Expanded Botox (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
NORTH CHICAGO, Ill., July 29, 2021 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of Botox® ...
Ipsen Announces Updated Indication for Dysport (abobotulinumtoxinA) for the Treatment of Spasticity in Children
CAMBRIDGE, Mass.--(BUSINESS WIRE) July 09, 2020 --Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration...
FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
DUBLIN, June 21, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental biologics application (sBLA) for...
Merz North America Announces FDA Approval of Xeomin (incobotulinumtoxinA) for Treatment of Adult Upper Limb Spasticity
RALEIGH, N.C.- December 23, 2015 --Merz North America, U.S. affiliate of the global Merz Pharma Group, announces that Xeomin (incobotulinumtoxinA) has received U.S. FDA approval for the treatment of...
Ipsen Announces FDA Approval of Dysport (abobotulinumtoxinA) for Upper Limb Spasticity
Paris (France), 16 July 2015 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) f...